News & Updates

In men with nonmetastatic castration-resistant prostate cancer (M0CRPC), the prostate-specific antigen (PSA) doubling time and the time to castration resistance (TTCRPC) predict cancer-specific survival (CSS), a recent study has found.

Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.

In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).

In prostate cancer patients, the initiation of androgen deprivation therapy (ADT) lowers the concentrations of 13 circulating steroids, according to a new study.

The addition of apatinib to vinorelbine appears to prolong progression-free survival in patients with advanced triple-negative breast cancer (TNBC) with failed first- or second-line treatment, as shown in the results of a phase II study.

A combination regimen comprising apatinib, a small-molecule TKI*, and pegylated liposomal doxorubicin (PLD) led to improved progression-free survival (PFS) in women with platinum-resistant recurrent ovarian cancer (PROC), results of the APPROVE trial suggest.

Among patients who undergo distal gastrectomy for gastric cancer, the risk of developing delayed gastric emptying (DGE) appears to be higher among women and those with diabetes, according to a recent study.

A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.